Equities Analysts Set Expectations for IQVIA FY2026 Earnings

IQVIA Holdings Inc. (NYSE:IQV) – Equities researchers at Leerink Partnrs lowered their FY2026 EPS estimates for IQVIA in a report issued on Tuesday, November 19th. Leerink Partnrs analyst M. Cherny now expects that the medical research company will post earnings of $12.46 per share for the year, down from their prior estimate of $12.49. The consensus estimate for IQVIA’s current full-year earnings is $10.17 per share. Leerink Partnrs also issued estimates for IQVIA’s FY2027 earnings at $13.78 EPS.

Several other equities research analysts also recently commented on IQV. Leerink Partners reiterated an “outperform” rating and issued a $248.00 price objective (down from $260.00) on shares of IQVIA in a report on Tuesday. Evercore ISI decreased their target price on IQVIA from $270.00 to $265.00 and set an “outperform” rating on the stock in a report on Tuesday, October 8th. Royal Bank of Canada reaffirmed an “outperform” rating and set a $270.00 price target on shares of IQVIA in a report on Friday, November 1st. Barclays lowered their price objective on IQVIA from $260.00 to $255.00 and set an “overweight” rating on the stock in a research report on Friday, November 1st. Finally, Morgan Stanley dropped their target price on shares of IQVIA from $280.00 to $265.00 and set an “overweight” rating for the company in a research report on Monday, November 4th. Four equities research analysts have rated the stock with a hold rating, fifteen have given a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $256.50.

IQVIA Trading Up 2.1 %

Shares of NYSE IQV opened at $201.82 on Thursday. IQVIA has a 1 year low of $187.62 and a 1 year high of $261.73. The company has a debt-to-equity ratio of 1.76, a current ratio of 0.81 and a quick ratio of 0.81. The stock has a market cap of $36.63 billion, a P/E ratio of 26.49, a price-to-earnings-growth ratio of 1.97 and a beta of 1.51. The firm has a 50-day moving average of $222.67 and a 200 day moving average of $227.18.

Institutional Trading of IQVIA

Several institutional investors have recently made changes to their positions in IQV. First Foundation Advisors increased its position in shares of IQVIA by 3.8% during the 2nd quarter. First Foundation Advisors now owns 1,161 shares of the medical research company’s stock worth $245,000 after purchasing an additional 43 shares during the last quarter. Invera Wealth Advisors LLC increased its position in shares of IQVIA by 0.3% during the second quarter. Invera Wealth Advisors LLC now owns 14,506 shares of the medical research company’s stock valued at $3,183,000 after acquiring an additional 46 shares during the last quarter. Private Trust Co. NA raised its stake in shares of IQVIA by 10.7% in the 3rd quarter. Private Trust Co. NA now owns 485 shares of the medical research company’s stock valued at $115,000 after acquiring an additional 47 shares during the period. Covestor Ltd lifted its holdings in shares of IQVIA by 45.3% in the 1st quarter. Covestor Ltd now owns 154 shares of the medical research company’s stock worth $39,000 after acquiring an additional 48 shares during the last quarter. Finally, Oregon Public Employees Retirement Fund increased its holdings in IQVIA by 0.3% in the 2nd quarter. Oregon Public Employees Retirement Fund now owns 15,668 shares of the medical research company’s stock valued at $3,313,000 after purchasing an additional 48 shares during the last quarter. Hedge funds and other institutional investors own 89.62% of the company’s stock.

Insider Buying and Selling at IQVIA

In related news, insider Eric Sherbet sold 1,300 shares of the company’s stock in a transaction dated Tuesday, August 27th. The shares were sold at an average price of $246.33, for a total value of $320,229.00. Following the completion of the sale, the insider now owns 19,536 shares of the company’s stock, valued at approximately $4,812,302.88. This represents a 6.24 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this link. 1.60% of the stock is currently owned by insiders.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.